Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2829258 | 0.94 | SLC6A9 (0.48) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL2825254 | 0.92 | SLC6A9 (0.46) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL2825959 | 0.90 | SLC6A9 (0.45) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL2825376 | 0.89 | SLC6A9 (0.56) | SLC6A9KCNH2 | |
| SCHEMBL2827864 | 0.87 | SLC6A9 (0.58) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL2825224 | 0.86 | SLC6A9 (0.66) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL2832016 | 0.86 | SLC6A9 (0.57) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL2825795 | 0.86 | SLC6A9 (0.61) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL2827870 | 0.85 | SLC6A9 (0.61) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL2828779 | 0.84 | SLC6A9 (0.71) | SLC6A9KCNH2SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220744-B2 | Monocyclic substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220744-B2 | Monocyclic substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220744-B2 | Monocyclic substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060167009-A1 | Monocyclic substituted phenyl methanones | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | US | disclosed |
| WO-2006072436-A1 | [4-(HETEROARYL) PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167009-A1 | Monocyclic substituted phenyl methanones | SLC1A2, SULT2A1, SLC6A5 | SLC6A9 23/4885KCNH2 1808/4885SLC6A5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.